医学临床研究
  2025年6月13日 星期五           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2024, Vol. 41 Issue (7): 1044-1047    DOI: 10.3969/j.issn.1671-7171.2024.07.024
  论著 本期目录 | 过刊浏览 | 高级检索 |
戈舍瑞林联合腹腔镜手术治疗子宫内膜异位症合并不孕症患者的临床疗效及安全性观察
刘莉, 石光辉, 郑振丽
周口市中心医院妇产科,河南 周口 466000
Clinical Efficacy and Safety Observation of Goserelin Combined with Laparoscopic Surgery in the Treatment of Endometriosis Complicated with Infertility Patients
LIU Li, SHI Guanghui, ZHENG Zhenli
Department of Obstetrics and Gynecology, Zhoukou Central Hospital,Zhoukou Henan 466000
全文: PDF (1174 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨戈舍瑞林联合腹腔镜手术治疗子宫内膜异位症合并不孕症患者的临床疗效及安全性。【方法】选取2019年7月至2020年7月本院收治的88例子宫内膜异位症合并不孕症患者,按照随机数字表法分为观察组(采用戈舍瑞林联合腹腔镜手术治疗)与对照组(采用腹腔镜手术治疗),每组44例。比较两组治疗效果、治疗期间不良反应总发生率、术后2年的子宫内膜异位症复发率和妊娠率及治疗前和治疗后6个月血清卵泡刺激素(FSH)、黄体生成素(LH)、雌二醇(E2)、谷胱甘肽过氧化酶(GSH-PX)、活性氧簇(ROS)水平。【结果】观察组总有效率显著高于对照组(P<0.05)。治疗后,两组FSH、LH、E2、ROS水平显著低于治疗前,且观察组FSH、LH、E2、ROS水平低于对照组(P<0.05);治疗后,两组GSH-PX水平显著高于治疗前,且观察组GSH-PX水平高于对照组。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。观察组复发率显著低于对照组(P<0.05),妊娠率显著高于对照组(P<0.05)。【结论】戈舍瑞林联合腹腔镜手术在子宫内膜异位症合并不孕症患者的治疗中效果较好,可调节患者性激素水平,改善氧化应激反应,降低复发率,提高妊娠率,且安全性较好。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
刘莉
石光辉
郑振丽
关键词 子宫内膜异位症/外科学不育,女性戈舍瑞林/治疗应用腹腔镜检查治疗结果    
Abstract:【Objective】 To explore the clinical efficacy and safety of goserelin combined with laparoscopic surgery in the treatment of endometriosis complicated with infertility patients.【Methods】A total of 88 patients with endometriosis complicated with infertility admitted to our hospital from July 2019 to July 2020 were randomly divided into the observation group (treated with goserelin combined with laparoscopic surgery) and the control group (treated with laparoscopic surgery) according to a random number table method, with 44 cases in each group. Two groups were compared in terms of treatment efficacy, overall incidence of adverse reactions during treatment, recurrence rate and pregnancy rate of endometriosis 2 years after surgery, as well as serum follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), glutathione peroxidase (GSH-PX), and reactive oxygen species (ROS) levels before and 6 months after treatment.【Result】The total effective rate of the observation group was significantly higher than that of the control group (P<0.05). After treatment, the levels of FSH, LH, E2, and ROS in both groups were significantly lower than before treatment, and the levels of FSH, LH, E2, and ROS in the observation group were lower than those in the control group (P<0.05); After treatment, the levels of GSH-PX in both groups were significantly higher than before treatment, and the observation group had higher levels of GSH-PX than the control group. There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05). The recurrence rate of the observation group was significantly lower than that of the control group (P<0.05), and the pregnancy rate was significantly higher than that of the control group (P<0.05). 【Conclusion】 The combination of goserelin and laparoscopic surgery is effective in the treatment of endometriosis complicated with infertility. It can regulate the patient's sex hormone levels, improve oxidative stress response, reduce recurrence rate, increase pregnancy rate, and has good safety.
Key wordsEndometriosis/SU    Infertility, Female    Goserelin/TU    Laparoscopy    Treatment Outcome
收稿日期: 2022-09-06     
中图分类号:  R711.71  
引用本文:   
刘莉, 石光辉, 郑振丽. 戈舍瑞林联合腹腔镜手术治疗子宫内膜异位症合并不孕症患者的临床疗效及安全性观察[J]. 医学临床研究, 2024, 41(7): 1044-1047.
LIU Li, SHI Guanghui, ZHENG Zhenli. Clinical Efficacy and Safety Observation of Goserelin Combined with Laparoscopic Surgery in the Treatment of Endometriosis Complicated with Infertility Patients. JOURNAL OF CLINICAL RESEARCH, 2024, 41(7): 1044-1047.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.07.024     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I7/1044
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn